Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia

Pediatric Blood & Cancer
Beata Zalewska-SzewczykJerzy Bodalski

Abstract

L-asparaginase is a basic agent of antileukemic therapy, but allergic reactions against the drug and the development of anti-asparaginase antibodies are significant side-effects. The aim of our study was to estimate the presence of anti-asparaginase antibodies and to correlate the results with clinically apparent allergic reactions and with L-asparaginase activity during the treatment. We examined 13 children with newly diagnosed acute lymphoblastic leukemia (ALL), treated according to the Polish Pediatric Leukemia/Lymphoma Group protocol, based on ALL-BFM 95. Enzyme activity was estimated in serum samples, collected before each L-asparaginase administration, using the photometrical method. Anti-asparaginase antibody concentration was measured by enzyme-linked immunosorbent assay (ELISA) at the two time points: at the last day of L-asparaginase treatment in the induction and the reinduction phase. The mean L-asparaginase activity was 273 IU/L in the induction phase; no anti-asparaginase antibodies in this phase of treatment were found. The mean L-asparaginase activity was 425 IU/L in the reinduction phase of treatment; in five children anti-asparaginase antibodies were detected. In four of these five children low L-asparaginase...Continue Reading

References

Sep 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B L AsselinH J Cohen
Aug 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J BoosH Jürgens
Oct 13, 1998·Critical Reviews in Oncology/hematology·H J Müller, J Boos
Mar 29, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M H WooM V Relling
Apr 13, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C RizzariM D'Incalci
Apr 30, 2002·Medical and Pediatric Oncology·Birgitte Klug AlbertsenNiels T Carlsen

❮ Previous
Next ❯

Citations

Jun 15, 2013·European Journal of Clinical Pharmacology·Antonio RuggieroRiccardo Riccardi
Feb 3, 2009·Clinical and Experimental Medicine·Beata Zalewska-SzewczykWojciech Młynarski
May 28, 2010·Journal of Pediatric Hematology/oncology·Sinan AkbayramAhmet Faik Oner
Mar 17, 2007·Critical Reviews in Biotechnology·Neelam VermaSneh Anand
Aug 13, 2009·Pediatric Blood & Cancer·Lynda M VroomanLewis B Silverman
Jan 29, 2010·Pediatric Blood & Cancer·Dominik SchreyJoachim Boos
Dec 17, 2008·The Journal of Allergy and Clinical Immunology·Ozge Uysal SoyerBulent Enis Sekerel
Jul 22, 2016·Journal of Pharmacology & Pharmacotherapeutics·Rachel A EglerYousif Matloub
Sep 15, 2020·Preparative Biochemistry & Biotechnology·Rominne Karla Barros FreireAdalberto Pessoa Junior
Jul 29, 2017·Journal of Hematology & Oncology·Marcus Kwong Lam Fung, Godfrey Chi-Fung Chan
Mar 4, 2019·Pharmacological Reports : PR·Justyna WalenciakBeata Zalewska-Szewczyk
Jan 26, 2020·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Irem Turgay YagmurEmine Dibek Misirlioglu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.